OBJECTIVES: Cachexia has been shown to be related to mortality in patients with advanced cancers and chronic obstructive pulmonary disease. Smokers receiving surgery for lung cancer are thought to be at risk of developing cachexia postoperatively. We aimed to investigate whether 2 surrogate variables for cachexia, body mass index (BMI) and C-reactive protein (CRP) level, are predictive of mortality in smokers after complete resection of non-small-cell lung cancer.
INTRODUCTION
Recurrence rates after the complete resection of non-small-cell lung cancer (NSCLC) have recently been reported to be 25-41%, depending on pathological stage and perioperative treatments [1] [2] [3] . The prognosis of postoperative recurrence is generally poor, and mortality in patients with completely resected NSCLC occurs mainly as a result of the progression of recurrence [2, 4] . On the other hand, lung cancer patients often have histories of heavy smoking and chronic obstructive pulmonary disease (COPD), which is one of the leading causes of death worldwide [5] . Many patients who undergo complete resection of NSCLC are expected to die of diseases of the respiratory system, regardless of recurrence. Cachexia is a wasting syndrome that accompanies cancer, COPD, cardiac disease and other conditions [6] [7] [8] . Several factors that are representative of cachexia, such as body mass index (BMI), loss of body weight, and sarcopenia (depletion of skeletal muscle), have been shown to be related to mortality in patients with advanced cancers, including lung cancer (cancer cachexia) [5, [8] [9] [10] , as well as in patients with COPD (pulmonary cachexia) [11] [12] [13] . However, the details of the mechanism of cachexia remain unclear, and an effective treatment has not yet been established [8] . There is an unmet need for investigations of the mechanism and treatment of cachexia, which should be pursued actively through clinical trials. Moreover, many patients with advanced cancer or COPD may have severe cachexia that is resistant to treatment.
Although the general condition of surgically indicated smokers with lung cancer may still be conserved, some of these patients are thought to be at risk of developing cachexia postoperatively. The effective treatment of cachexia may be able to improve their postoperative prognosis, and these patients may be appropriate candidates for clinical trials of cachexia treatment. The purpose of this study was to investigate whether surrogate variables of cachexia are predictive of mortality in smokers after the complete resection of NSCLC. Few reports have investigated this hypothesis.
MATERIALS AND METHODS
We conducted a retrospective study of 678 patients who underwent curative lobar resection for NSCLC at our hospital consecutively from 2006 to 2010. Cases treated with segmetectomy or wedge resection were excluded from this study. Patients with macroscopically or microscopically confirmed residual cancer were also excluded. We applied no specific inclusion or exclusion criteria for preoperative medicine intake, comorbidities, or infectious disease influencing BMI and serum C-reactive protein (CRP). This study was performed in accordance with the Helsinki Declaration and approved by our institutional review board. The need for patient consent was waived because all the data in this study were completely anonymized.
The 678 patients were divided into 421 smokers and 257 never smokers. Patients who reported no experience with smoking were defined as never smokers, and patients who reported otherwise were defined as smokers, regardless of whether they currently smoked. For each group, we investigated the clinicopathological factors that were associated with shorter overall survival (OS). Of the variables that were available for this study, CRP was regarded as a potential surrogate of cachexia because one of the key features of pulmonary cachexia is accelerated energy expenditure due to persistent inflammation [14] . Similarly, BMI and serum albumin were also regarded as potential surrogates of cachexia. We reviewed medical records and used BMI, CRP, serum albumin and other values that had been obtained immediately before the operation for our analyses.
Thoracotomy with posterolateral incision was usually performed in lobectomy. No complete thoracoscopic surgery was performed. When deciding upon the range of lymph node dissection, we considered the clinical or surgical stage of the lung cancer and the comorbidities of the patient. Postoperative follow-up was conducted every 3 months during the first 2 years, every 6 months during the next 2 years, and every 1 year afterward. The follow-up included screening the patients for recurrence via physical examination, tumour markers, chest radiography and computed tomography. Recurrence was diagnosed pathologically via biopsy or clinically based on the presence of nodules that were observed to grow on computed tomography or brain magnetic resonance imaging and exhibited accumulation on 2-[18]-fluoro-2-deoxy-Dglucose positron emission tomography. We did not routinely confirm the pathological diagnosis. Cases were officially diagnosed through the lung cancer board at our institute.
Statistical analysis
We used univariate analyses with the Log-rank test to screen for potential risk factors for postoperative OS. Continuous variables were dichotomized and converted to categorical variables using cut-off values that were chosen by maximizing the value of Youden's index on the receiver operating characteristic curve for mortality. The cut-off values for BMI and CRP were 20.6 kg/m 2 and 0.13 ng/ml. The area under the receiver operating characteristic curve and Youden's index for cut-off values were 0.53 and 0.073 for BMI and 0.62 and 0.23 for CRP, respectively. Variables that were significant in univariate analyses were included in a multivariate analysis, which was performed using the Cox proportional hazards model. Survival curves were estimated via the Kaplan-Meier method. All reported P-values are two-sided. P-values <0.1 were considered statistically significant in the univariate analyses and P-values <0.05 were considered statistically significant in the multivariate analysis. All statistical analyses were performed using JMP software, version 9.0.0 (SAS Institute, Cary, NC, USA)
RESULTS

Overall survival in smokers and never smokers
Four hundred twenty-one smokers and 257 never smokers were analysed. The median follow-up period was 60 months (range, 2-108 months). We had to discontinue the follow-up for 44 patients (6.5%). The 3-and 5-year OS rates were 86.1% and 75.9% in smokers, respectively, and 94.5% and 87.8% in non-smokers, respectively. Smokers had significantly a poorer prognosis than did non-smokers (P < 0.0001; Fig. 1A ). The 3-and 5-year recurrencefree rates were 80.1% and 75.1% in smokers, respectively, and 82.9% and 79.2% in non-smokers, respectively. The recurrencefree rates of smokers and non-smokers did not differ significantly (P = 0.31; Fig. 1B ). Among the smokers, there were 111 deaths during the follow-up period. Causes of death included recurrence of lung cancer (68 cases, 61%), pulmonary diseases (18 cases, 16%), other cancers (9 cases, 8%). In contrast, no death due to pulmonary disease was noted among the never smokers (Table 1) .
Factors associated with overall survival in smokers and never smokers
The clinicopathological characteristics that were investigated for smokers are shown in Table 2 . The smoker group included 355 men and 66 women. The median Brinkman index (BI) was 840 (range, 0.1-1280). Seventy percent of the patients in this group were heavy smokers with a BI of more than 600. The BI is defined as the number of cigarettes smoked per day Â the number of years of smoking reported by the patient before being diagnosed with lung cancer. Univariate analyses indicated that BMI, CRP, albumin, sex, age, parameters of respiratory function, tumour factors, perioperative therapies and postoperative complications were significantly associated with OS (P-value < 0.1) ( Table 2 ). Multivariate analysis indicated that preoperative BMI < _ 20.6 kg/m 2 and CRP > _ 0.13 ng/ml were independent risk factors for poorer prognosis in the smoker group (Table 3) . In contrast, preoperative BMI and CRP were not significantly associated with shorter OS in univariate analyses of the never smoker group.
Grouping based on body mass index and C-reactive protein level
We divided the patients into 3 risk groups according to BMI and CRP level: a high-risk group, an intermediate-risk group and a low-risk group (Table 4) . Supplementary Material, Table S1 compares the characteristics of these 3 groups. The 5-year OS rates in the high-, intermediate-and low-risk groups were 55.4, 70.7 and 86.6%, respectively. This grouping provided a significant stratification of the OS curves ( Fig. 2A) . The 5-year recurrence-free rates in the high-, intermediate-and low-risk groups were 66.8, 73.1 and 79.7%, respectively. There was no significant difference between these rates (Fig. 2B) . Figure 3A shows post-recurrence survival among those patients who developed recurrence. Postrecurrence survival was significantly worse in the high-and intermediate-risk groups than in the low-risk group. Postrecurrence therapies might play a large role in the prognosis of recurrent lung cancer. However, in the high-, intermediate-and low-risk groups, post-recurrence therapies were attempted for 12 of 15, 34 of 53 and 28 of 33 patients with recurrence, respectively, which showed no significant difference (P = 0.19, v 2 test, Supplementary Material, Table S1 ). Figure 3B shows the OS rates in patients who did not develop recurrence during the study. Prognosis was significantly worse in the high-risk group.
DISCUSSION
Involuntary emaciation has previously been recognized both as a finding that accompanies several underlying diseases, such as advanced cancer and COPD, and as a sign of poor prognosis. The mechanisms of cachexia are multifactorial and complex and, consequently, it is not improved by simple nutritional therapy. The understanding of cachexia's pathophysiology and molecular biology has progressed over the past decades. It has been reported that underweight patients with COPD could achieve weight gain, improved respiratory function, and improved exercise performance via a modified nutritional and rehabilitative program [15] . In addition, several kinds of novel pharmacological therapies have been explored [6, [15] [16] [17] . However, most studies of treatments of cachexia have been preliminary and have used a single-institute design. No treatment modality for cachexia has been demonstrated to confer improvements in long-term prognosis in the more robust context of a clinical trial [8, 18] . Furthermore, the studies on cachexia that have been performed to date have mostly included unselected patients with weight loss of any aetiology and diverse severities of the condition [7] . Moreover, it is only in the past several years that definitions of and criteria for the severity of generic cachexia and cancer cachexia have been proposed in consensus conferences [6, 7] , and these definitions have yet to be validated by prospective clinical trials [8] . Currently, in order to evaluate promising treatments for cachexia, it is important to perform organised clinical trials of patients with cachexia with homogeneous backgrounds and severities. In this study, we found that preoperative low BMI and elevated CRP were predictive factors for poor prognosis in smokers who had undergone complete resection of NSCLC, independently of age and the staging of lung cancer. It was also verified that patients belonging to the high-risk group (which was based on preoperative BMI and CRP level) had shorter durations of survival after recurrence. Even among patients who did not develop recurrence, the high-risk group had a poorer prognosis, with deaths mainly being attributed to pulmonary diseases, such as pneumonia, and cancers other than lung cancer. The findings are compatible with the idea that the poor postoperative prognosis in patients with preoperative low BMI and elevated CRP resulted from the progression of cachexia. The high-risk group included more heavy smokers with BI values > _ 880 (Supplementary Material, Table S1 ). Patients in the high-risk group also seem to have generally damaged lungs and excessive inflammation due to smoking and COPD. It is natural that smokers are at risk of being cachexic after pulmonary resection for lung cancer; energy expenditure and inflammation are probably elevated because of increasing respiratory work and exacerbating COPD or postoperative pneumonia. Moreover, if recurrence or another cancer occurs, the cachexic tendency of the patients will be accelerated. Several reports have described sarcopenia as being associated with toxicities from many kinds of chemotherapy that are administered for cancer [19] [20] [21] [22] [23] . The susceptibility of individuals with sarcopenia to infections has also been noted previously [24] . Martin and co-workers noted that both the premature termination of cancer treatment Three cases were all left pneumonectomies. d Short-term postoperative complications. All types and grades of short-term postoperative complications described on medical records were included. *Using P < 0.1 as a criterion for statistical significance, variables that were significant in the univariate analyses were included in the multivariate analysis.
and infection are possible contributors to the shortened survival durations of patients with sarcopenia [10] . We think that these factors explain the significant differences in post-recurrence survival between the groups that were stratified by BMI and CRP. Previous reports have described low BMI as a risk factor for short-term morbidity and mortality after resection of lung cancer [25] [26] [27] , but few studies have investigated the association between BMI and long-term prognosis. Attaran and co-workers [28] reported that patients with BMI > _ 30 kg/m 2 have better survival than those with a BMI <30 kg/m 2 after pulmonary resection for lung cancer. In their report, the authors considered the positive effects that obesity would have (the so-called 'obesity paradox'), rather than the negative effects that leanness would have. Other than the nutritional aspect to the obesity paradox, its underlying mechanisms have been unclear. In a metaanalysis, elevated CRP was associated with the prognosis of NSCLC patients [29] . However, in groups of patients with operable NSCLC, CRP has rarely been identified as a prognostic factor.
Patients who smoke and have operable NSCLC are expected to be appropriate candidates for clinical trials of cachexia treatment. They are at risk of developing cachexia postoperatively.
Nevertheless, the preoperative extent of cachexia does not appear to be very severe among these patients. As recommended by an international consensus conference [7] , the staging of cancer cachexia is divided into 3 degrees: pre-cachexia, cachexia and refractory cachexia. In the consensus, it was pointed out that previous cachexia intervention trials included patients in the terminal cachexic stage. At the least, the very advanced stages of cachexia would not be found among those smokers who would find surgery for NSCLC tolerable. If an effective treatment for cachexia could be administered to these patients perioperatively-especially to patients in the high-risk group for postoperative cachexia-then the postoperative prognosis might improve, regardless of the recurrence of NSCLC. Such a development would provide considerable benefit to patients.
It is interesting that, in the never smokers group, low BMI and elevated CRP were not associated with poor prognosis after pulmonary resection for NSCLC. BI > _ 880 was significantly associated with postoperative prognosis in smokers. In contrast, being a current smoker was not significantly associated with postoperative prognosis. There were more smokers with BI > _ 880 in the highrisk group, which had been defined based on BMI and CRP. These findings may suggest that the postoperative cachexia and prognosis are deeply related to accumulated smoking history. Never smoking is thought to be one of the strongest protective factors for this kind of cachexia. In the future, we should study how light-to-moderate smoking has influence on postoperative cachexia.
Preoperative serum albumin was not associated with postoperative mortality in our study. We expect that the absence of this association is attributable to the presence of only a few cases with a preoperative serum albumin level of less than 3.5 mg/dl. It has been demonstrated that the Glasgow prognostic score, which is composed of serum albumin and CRP, is a prognostic factor for operable and inoperable NSCLC [30] . However, our results suggest that the combination of BMI and CRP is a better predictor of postoperative prognosis than is Glasgow prognostic score in operable NSCLC.
Our study has some limitations. First, it is a retrospective study on data from a single institute. The prospective accumulation of data from multiple centres is necessary. Second, we did not directly demonstrate differences in postoperative cachexia progression between the groups that were stratified by preoperative BMI and CRP. However, we could not obtain the detailed postoperative changes in BMI, CRP and other surrogate markers of cachexia in this study. Direct measures of postoperative cachexia remain a topic for future research that we need to consider. Third, the simple combination of BMI and CRP may be less predictive of postoperative cachexia and prognosis than other variables or indices, which were not investigated in the current study. In Western countries where the proportion of overweightobese patients is increasing, it was reported that muscle depletion is superior to BMI as a prognostic factor [10] . Jafri and colleagues [8] introduced a 'cachexia index' for estimating prognosis after the diagnosis of advanced NSCLC. Their cachexia index includes skeletal mass index (skeletal muscle area at the third lumber vertebra on computed tomography, divided by height in meters squared), serum albumin, and the neutrophil-tolymphocyte ratio. Preoperative depletion of body weight or muscle loss can also represent cachexic tendencies more directly. However, these data are difficult and time-consuming to obtain with precision. In contrast, BMI and CRP data are easily to obtain. The cut-off values of BMI and CRP may also need to be studied further in analyses that include more cases. The area under the receiver operating characteristic curve and Youden's index for the cut-off values of BMI were not especially high. One reason for the relatively low values seems to be the presence of significantly more women in the BMI < _ 20.6 group, which made the survival curve of this group better and the difference between groups smaller. Finally, complete thoracoscopic surgery for lung cancer is becoming a prevailing therapeutic strategy, although it has not yet been introduced at our hospital. It would be interesting to investigate whether complete thoracoscopic surgery has a favourable effect on postoperative cachexia.
In conclusion, we found that preoperative low BMI and elevated CRP are predictive factors for poor prognosis in smokers who have undergone complete resection of NSCLC. The predictive abilities of these factors are probably attributable to the progression of cachexia. An effective treatment for cachexia may improve postoperative prognosis advantageously in smokers for whom the radical resection of NSCLC is tolerable. These patients are expected to be appropriate candidates for clinical trials of cachexia treatment.
